News & Events
-
December 20, 2011
Critical Path Institute and Hamner Institutes for Health Sciences Announce Collaboration to Improve Safety of Medical Product Development
Critical Path Institute(C-Path)and The Hamner Institutes for Health Sciences (The Hamner) announced today that they have signed a Memorandum of Understanding (MOU) to develop innovative, collaborative activities in the areas of regulatory science research for predicting, detecting and monitoring liver safety issues during the development of new medicines. -
December 1, 2011
Critical Path Institute Gathers Cross-Sector Innovators at Global Conference on Drug Development
Hundreds of leaders from cross-sector arenas in government, academia, the biotechnology and pharmaceutical industry, and patient advocacy organizations gathered over the past two days at Critical Path Institute’s Creating Consensus Science: Tools and Tactics for Next-Gen Drug Development conference to articulate a common commitment to the future of global collaborative efforts that develop innovative tools... - December 1, 2011
-
November 30, 2011 - December 1, 2011
C-Path’s Creating Consensus Science Conference Nov-Dec 2011
Creating Consensus Science. New Tools and Tactics for Next-Gen Drug Development Wednesday, November 30, 2011 Welcome Margaret Hamburg – Keynote Speaker Session I: Data Standards and Clinical Trial Databases as Tools Session II: Biomarkers as Tools Session III: Patient-Reported Outcome Instruments as Tools Session IV: Quantitative Disease Progression Models as Tools Closing Remarks Day 1... -
November 9, 2011
CPTR Yields Progress: New Five-Way Agreement Among Pharmas and NGOs will Speed Development of TB Drug Combinations
The Critical Path to TB Drug Regimens (CPTR) today announced an innovative agreement between AstraZeneca, Sanofi, Tibotec, TB Alliance, and the World Health Organization to share information on tuberculosis (TB) compounds within their respective drug pipelines to quickly identify and work together to develop the most promising TB drug regimen, regardless of sponsor. Previously, development...
